Pasithea Therapeutics
KTTA
11 hedge funds and large institutions have $406K invested in Pasithea Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0.05% less ownership
Funds ownership: 0.15% → 0.11% (-0.05%)
61% less capital invested
Capital invested by funds: $1.03M → $406K (-$626K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$30.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.37K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.27K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5K |
| 5 |
JP Morgan Chase
New York
|
+$2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$209K |
| 2 |
OWP
Old Well Partners
Charlotte,
North Carolina
|
-$42K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$360 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KPF
1
K2 Principal Fund
Toronto,
Ontario, Canada
| $181K | -$209K | -10,468 | -43% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $103K | +$360 | +18 | +0.2% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $63K | -$360 | -18 | -0.4% |
|
|
VF
4
Virtu Financial
New York
| $20K | +$30.9K | +1,547 | New |
|
5
State Street
Boston,
Massachusetts
| $15.4K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $10K | +$9.37K | +469 | +166% |
|
|
7
UBS Group
Zurich,
Switzerland
| $8.15K | +$7.27K | +364 | +133% |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$5K | +250 | New |
|
|
9
JP Morgan Chase
New York
| $2K | +$2K | +100 | +200% |
|
10
Wells Fargo
San Francisco,
California
| $74 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $21 | +$40 | +2 | New |
|
|
OWP
12
Old Well Partners
Charlotte,
North Carolina
| – | -$42K | -1,650 | Closed |
|
KTTA Hedge Fund Activity: Q4 2022 in Review
11 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2022, worth a combined $406K — down 61% from $1.03M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KTTA positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $30.9K. The largest seller was K2 Principal Fund, cutting an estimated $209K.
- 11 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2022, up from 9 in Q3 2022.
- Funds reported $406K of Pasithea Therapeutics stock for Q4 2022, down 61% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics positions in Q4 2022 and 1 closed out, a net change of +2 holders.
- The largest Pasithea Therapeutics buyer in Q4 2022 was Virtu Financial, an estimated $30.9K added.
- The largest Pasithea Therapeutics seller in Q4 2022 was K2 Principal Fund, an estimated $209K sold.
Based on aggregated 13F filings for Q4 2022.